News
Gilead Sciences and the Global Fund to Fight AIDS, Tuberculosis and Malaria said on Wednesday they had finalized plans to ...
A secondary analysis of a large trial shows that exposure to the HIV drug abacavir is linked to an elevated risk for major ...
Lenacapavir offers twice-yearly HIV prevention with near-complete protection in clinical trials. Clinical trials show ...
While the National Treasury has released R700m, the Bill and Melinda Gates Foundation and the Wellcome Trust will ...
In early 2025, the US decision to halt foreign aid for HIV/AIDS programs triggered global concerns about a potential ...
National Treasury has allocated R753 million to the Department of Health -- under Section 16 of the Public Finance Management ...
Lower-income countries will gain access to a "game-changing" HIV prevention drug with a new deal signed between US ...
Several Midwestern Cities have been designated as HIV “hotspots” due to the rising number of new cases; and the South ...
Gilead announced a deal to get its groundbreaking HIV prevention drug to lower income countries. Notably, the deal does not ...
Rep. Marjorie Taylor Greene (R-GA) ranted about how the U.S. sends money to Africa to prevent the spread of HIV, arguing that ...
People living with HIV face unique oral health challenges that require special attention and care. The virus's impact on the ...
Gilead Sciences (GILD) stock in focus as the company joins The Global Fund to expand access to lenacapavir, an HIV PrEP ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results